Pyxis Oncology (PYXS) Price & Analysis

Compare

514 Followers

PYXS Stock Chart & Stats

$3.91

-$0.10(-5.75%)

At close: Jan 08 4:00 PM EST

$3.91

-$0.10(-5.75%)

Day’s Range― - ―

52-Week Range$0.83 - $5.39

Previous CloseN/A

Volume258.73K

Average Volume (3M)820.42K

Market Cap

$243.45M

Enterprise Value$80.22M

Total Cash (Recent Filing)$77.73M

Total Debt (Recent Filing)$19.07M

Price to Earnings (P/E)―

Beta0.88

Next Earnings

Mar 25, 2026

EPS Estimate

-0.32

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.35

Shares Outstanding62,264,214

10 Day Avg. Volume740,100

30 Day Avg. Volume820,420

Financial Highlights & Ratios

PEG Ratio0.04

Price to Book (P/B)0.76

Price to Sales (P/S)5.65

P/FCF Ratio-1.57

Enterprise Value/Market Cap0.33

Enterprise Value/Revenue28.45

Enterprise Value/Gross Profit28.45

Enterprise Value/Ebitda-0.97

Forecast

1Y Price Target

$6.80

Price Target Upside73.91% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentPreliminary data from one of the cohorts is now expected earlier than previously guided, indicating a potential acceleration in clinical development.

Financial StabilityPyxis reported a cash level of $90.4 million, which should sustain company operations into the second half of 2026, indicating financial stability.

Strategic PartnershipsPyxis has a clinical trial collaboration agreement with Merck for the combination of MICVO with Keytruda, which could enhance treatment efficacy.

Bears Say

Clinical Data ConcernsInitial Phase I data of Micvo in head-and-neck cancer results as difficult to differentiate with only modest activity in other areas.

Data Timeline DelaysPreliminary data for 2/3L monotherapy in PD-1 and EGFR targeted therapy experienced patients are not expected until the first half of 2026, indicating a delay in the data timeline.

Financial ChallengesThe company has a limited cash runway of approximately one year, which could pose a financial challenge if additional funding is not secured.

Pyxis Oncology News

Pyxis Oncology reports Q3 EPS (35c), consensus (34c)

“In the dynamic landscape of emerging clinical-stage therapies for patients with recurrent and metastatic head and neck squamous...

7d ago

PYXS

Pyxis Oncology resumed with a Buy at Stifel

Stifel analyst Stephen Willey resumed coverage of Pyxis Oncology (PYXS) with a Buy rating and $9 price target...

7d ago

PYXS

Promising Developments in Pyxis Oncology’s MICVO Drive Buy Rating

LifeSci Capital analyst Sam Slutsky has maintained their bullish stance on PYXS stock, giving a Buy rating yesterday....

6d ago

PYXS

Pyxis Oncology’s Promising Study on PYX-201 and Pembrolizumab in Advanced Solid Tumors

Pyxis Oncology, Inc. (($PYXS)) announced an update on their ongoing clinical study. Pyxis Oncology, Inc. is conducting a...

13d ago

PYXS

Pyxis Oncology’s PYX-201 Study: A Promising Step in Solid Tumor Treatment

Pyxis Oncology, Inc. (($PYXS)) announced an update on their ongoing clinical study. Pyxis Oncology, Inc. is conducting a...

13d ago

PYXS

Pyxis Oncology appoints Alex Kane as SVP, IR, capital markets

Pyxis Oncology (PYXS) announced the appointment of Alex Kane, MBA, as Senior Vice President, Investor Relations & Capital...

1M ago

PYXS

Pyxis Oncology initiated with a Buy at Guggenheim

Guggenheim initiated coverage of Pyxis Oncology (PYXS) with a Buy rating and $5 price target The firm believes...

2M ago

PYXS

Pyxis Oncology initiated with a Buy at Guggenheim

Guggenheim initiated coverage of Pyxis Oncology (PYXS) with a Buy rating and $5 price target Published first on...

2M ago

PYXS

Optimistic Buy Rating for Pyxis Oncology Driven by Promising MICVO Developments and Strategic Merck Collaboration

LifeSci Capital analyst Sam Slutsky has maintained their bullish stance on PYXS stock, giving a Buy rating today....

3M ago

PYXS

Buy Rating for Pyxis Oncology: Promising Prospects for Micvo and Strong Financial Position

In a report released today, Jeffrey La Rosa from Leerink Partners maintained a Buy rating on Pyxis Oncology,...

3M ago

PYXS

Pyxis Oncology Reports Q2 2025 Financial Results

Pyxis Oncology, Inc. ( ($PYXS) ) has released its Q2 earnings. Here is a breakdown of the information...

3M ago

PYXS

Pyxis Oncology reports Q2 EPS (30c), consensus (35c)

Reports Q2 revenue $2.8M vs. $0 last year. “We are invigorated by the progress we’re making, particularly in...

3M ago

PYXS

Pyxis Oncology Updates Phase 1 Trial Enrollment

Pyxis Oncology ( ($PYXS) ) has issued an update. On July 31, 2025, Pyxis Oncology revised patient enrollment...

3M ago

PYXS

Crescent Biopharma appoints Jan Pinkas as CSO

Crescent Biopharma (CBIO) announced the appointment of Jan Pinkas, Ph.D., as chief scientific officer. Prior to joining Crescent,...

4M ago

CBIO

PYXS

PYXS FAQ

What was Pyxis Oncology’s price range in the past 12 months?

Pyxis Oncology lowest stock price was $0.83 and its highest was $5.39 in the past 12 months.

What is Pyxis Oncology’s market cap?

Pyxis Oncology’s market cap is $243.45M.

When is Pyxis Oncology’s upcoming earnings report date?

Pyxis Oncology’s upcoming earnings report date is Mar 25, 2026 which is in 135 days.

How were Pyxis Oncology’s earnings last quarter?

Pyxis Oncology released its earnings results on Nov 03, 2025. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.334 by -$0.016.

Is Pyxis Oncology overvalued?

According to Wall Street analysts Pyxis Oncology’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Pyxis Oncology pay dividends?

Pyxis Oncology does not currently pay dividends.

What is Pyxis Oncology’s EPS estimate?

Pyxis Oncology’s EPS estimate is -0.32.

How many shares outstanding does Pyxis Oncology have?

Pyxis Oncology has 62,264,214 shares outstanding.

What happened to Pyxis Oncology’s price movement after its last earnings report?

Pyxis Oncology reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.334. Following the earnings report the stock price went up 7.022%.

Which hedge fund is a major shareholder of Pyxis Oncology?

Currently, no hedge funds are holding shares in PYXS

Pyxis Oncology Stock Smart Score

Neutral

Fundamentals

Return on Equity

-87.28%

Trailing 12-Months

Asset Growth

-45.93%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Pyxis Oncology

Pyxis Oncology, Inc. (PYXS) is a biopharmaceutical company focused on developing novel antibody-drug conjugates (ADCs) and immuno-oncology therapeutics for the treatment of cancer. The company operates within the healthcare sector, primarily targeting oncology as its core field. Pyxis Oncology aims to address unmet medical needs by leveraging its proprietary platforms to discover and develop innovative therapies that improve patient outcomes.

Pyxis Oncology (PYXS) Earnings & Revenues

Historic Earnings Reports

PYXS Stock 12 Month Forecast

Average Price Target

$6.80

▲(73.91% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","-1":"-$1","1.75":"$1.75","4.5":"$4.5","7.25":"$7.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.75,4.5,7.25,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.56,3.9784615384615387,4.396923076923077,4.815384615384615,5.233846153846153,5.6523076923076925,6.070769230769231,6.489230769230769,6.907692307692308,7.326153846153845,7.7446153846153845,8.163076923076924,8.581538461538461,{"y":9,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.56,3.809230769230769,4.058461538461539,4.3076923076923075,4.556923076923077,4.806153846153846,5.055384615384615,5.304615384615385,5.553846153846154,5.803076923076922,6.052307692307692,6.3015384615384615,6.55076923076923,{"y":6.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.56,3.670769230769231,3.7815384615384615,3.8923076923076922,4.003076923076923,4.113846153846154,4.224615384615385,4.335384615384616,4.446153846153846,4.556923076923077,4.667692307692308,4.7784615384615385,4.889230769230769,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.2,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.69,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.79,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.51,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.76,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.92,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.1,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.1,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.33,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.56,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >